Abstract

Veterinary Compounding for Myasthenia Gravis

Author(s): Davidson Gigi S

Issue: Sep/Oct 2008 - Veterinary Compounding

Page(s): 398-401

Download in electronic PDF format for $75
  • Veterinary Compounding for Myasthenia Gravis Page 1
  • Veterinary Compounding for Myasthenia Gravis Page 2
  • Veterinary Compounding for Myasthenia Gravis Page 3
  • Veterinary Compounding for Myasthenia Gravis Page 4

Abstract

Myasthenia gravis is a neuromuscular disease commonly encountered in veterinary medicine. With accurate diagnosis, treatment, and compliant caregivers, the prognosis for remission and a normal life is good. Unfortunately, drugs used to diagnose and treat myasthenia gravis are frequently unavailable due to manufacturer shortages. During these periods, compounding pharmacists can play a valuable role in maintaining a good quality of life for these patients by providing compounded versions of drugs that are commercially unavailable.

Related Keywords

  • formulations
  • myasthenia gravis
  • muscle disorders
  • dogs
  • veterinary medicine
  • muscle weakness
  • cats
  • edrophomium hydrochloride
  • acetylcholinesterase inhibitor
  • acetycholine
  • neurotransmitter
  • anticholinesterase agents
  • pyridostigmine bromide
  • cellulose
  • methylcellulose
  • excipients

Related Categories

  • EXCIPIENTS
  • FORMULATIONS
  • VETERINARY
  • MUSCULOSKELETAL DISORDERS
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
Sep/Oct 2008
Pg. 398-401
Veterinary Compounding for Myasthenia Gravis
Author(s): Davidson Gigi S
Mar/Apr 2001
Pg. 86-88
The Use of Psychoactive Agents in Veterinary Medicine
Author(s): Simpson Barbara S
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Sep/Oct 2019
Pg. 428-433
The Current Landscape of Veterinary Compounding in the Veterinary Setting
Author(s): Gochenauer Alexandria E, Rishniw Mark, Holmes Erin R, Forsythe Lauren R
Sep/Oct 2019
Pg. 422-427
The Current Landscape of Veterinary Compounding in the Pharmacy Setting
Author(s): Gochenauer Alexandria E, Holmes Erin R, Barber Katie E, Forsythe Lauren R
Jan/Feb 2004
Pg. 46-48
Basics of Compounding for Disorders of the External Ear
Author(s): Allen Loyd V Jr
Sep/Oct 2007
Pg. 357-362
United States Pharmacopeia Convention Standards and Clinical Information for Compounded Medications Used in Veterinary Medicine
Author(s): DeVeau Ian
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Nov/Dec 2006
Pg. 417-418
Compounding for Veterinary Medicine
Author(s): Fields Shannon W
Jul/Aug 1997
Pg. 222-227
Veterinary Compounding: A Bird's Eye View
Author(s): Jordan Dinah G
Sep/Oct 2008
Pg. 384-390
Canine Public Servants: Caring for Drug Detection Dogs
Author(s): Davidson Gigi S
Jul/Aug 2014
Pg. 278-286
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
May/Jun 2017
Pg. 234
Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 100-109
Compounded Pain Formulations: What is the Evidence?
Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Mar/Apr 2024
Pg. 136
Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base
Author(s): Allen Loyd V Jr
Sep/Oct 2014
Pg. 366-369
To Compound or Not to Compound: A Veterinary Transdermal Discussion
Author(s): Eichstadt Lauren R, Davidson Gigi S
Sep/Oct 2014
Pg. 411
Ephedrine Sulfate 50-mg/mL Injection
Author(s): Allen Loyd V Jr
May/Jun 2005
Pg. 233
Phenoxybenzamine Hydrochloride 5-mg Capsules, Veterinary
Author(s): Allen Loyd V Jr
May/Jun 2005
Pg. 227
Dipyrone 500-mg/mL Injection, Veterinary
Author(s): Allen Loyd V Jr